



ASX Announcement (426)
22 June 2011

Announcements Officer
Company Announcements Office
ASX Limited

1 for 2 non-renounceable pro rata entitlement offer
Letter to Eligible Shareholders
Extension of Closing Date – 12 July 2011

Further to the Company's announcement of 20 June 2011 and in accordance with ASX Listing Rules, please find attached documents mailed to Eligible Shareholders of Virax today.

Yours sincerely

John Morrison
Virax Holdings Limited
Company Secretary



000001 000 VHL
MR JOHN SMITH 1
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030

20 June 2011

**1 for 2 Rights Offer at 2.2 cents per share
To raise up to approximately \$2.0 million**

Virax Holdings Limited (ASX:VHL) announced on 20 June 2011 a two week extension to the closing date of the 1 for 2 Rights Offer. The Offer Document was despatched to Eligible Shareholders on 6 June 2011.

The revised key dates for the Offer (highlighted in bold below) - will now be as follows:

Announcement of the Offer	Wednesday, 25 May 2011
Record Date	7 pm (AEST), Thursday, 2 June 2011
Despatch of Offer Document and Entitlement and Acceptance forms	Monday, 6 June 2011
Closing Date	5 pm (AEST), Tuesday, 12 July 2011
Allotment of Shares	Tuesday, 19 July 2011
Holding statements expected to be despatched to shareholders	Wednesday, 20 July 2011
Trading of New Shares expected to commence on ASX	Thursday, 21 July 2011

This Rights Offer is to be complemented by Placements to raise \$3 million in total (including the amount raised under the Rights Offer). Shareholder approval for the placements is being sought at a general meeting convened for 24 June 2011. The amount raised through the Rights Offer will influence the amounts sought to be raised through the Placements.

The purpose of the fundraising is to fund the Company's development of its in-licensed Skin Cancer program TG1042 – focusing on Basal Cell Carcinoma.

In addition to the Company's focus on Basal Cell Carcinoma, I would also like to ensure that you are aware of the Company's announcement of 10 June 2011 about TG1042 and its use in an investigator led French trial into melanoma. A copy of that announcement accompanies this letter, for your information. This highlights the widespread utility of TG1042 in a range of skin cancers.

I encourage shareholders to support the Company and its fund raising initiatives. I remind you that the full details are in the Offer Document which was forward to all Eligible Shareholders on 6 June 2011.

On behalf of the Board.

Yours sincerely

Michael J Humphris
Chairman
Virax Holdings Limited



10 June 2011

ASX Code: VHL

Announcement #423

TG1042 SKIN CANCER IMMUNOTHERAPEUTIC UPDATE

FRENCH TRIAL IN MELANOMA

Key Points

- Nantes University Hospital in France is conducting a clinical trial in metastatic melanoma which combines TG1042 treatment and tumor infiltrating lymphocytes treatment. Preliminary results expected in early 2012.
- Melanoma application of TG1042 falls within Virax's worldwide exclusive License Agreement with leading French biopharmaceutical company Transgene to develop TG1042 in all forms of skin cancer.
- Melanoma trial emanates from collaboration between Transgene and Nantes University Hospital. Virax met with the Principal Investigator for this trial and has agreed to continue to support the collaboration. Melanoma is the most deadly form of skin cancer
- Virax continues to execute plans to move rapidly into Phase I/IIa Clinical Trials in Australia for TG1042 targeting Basal Cell Carcinoma, the world's most common form of cancer.

Australian biotechnology company Virax Holdings Limited (ASX: VHL) is pleased to provide the following update on its TG1042 skin cancer immunotherapeutic, including an ongoing clinical trial of TG1042 in combination with a novel cell-based therapy for the treatment of metastatic melanoma.

Virax's world-wide license for TG1042 is for all skin cancer applications. This compound is designed for direct (intra-tumoral) injection and has potential applications in a variety of different skin cancers including basal cell carcinoma (BCC), squamous cell carcinoma, melanoma and cutaneous lymphoma. TG1042 has already been in clinical trials for cutaneous lymphoma, a rare form of skin cancer, where it showed highly promising clinical efficacy.

Virax's focus for TG1042 is on Basal Cell Carcinoma skin cancer as it continues to execute plans to move rapidly into Phase I/IIa Clinical Trials, with a trial planned to commence later this year.

Virax representatives were in attendance at the American Society for Clinical Oncology (ASCO), the largest clinical cancer meeting in the world, held June 3-7 in Chicago. During ASCO, Virax met with Professor Brigitte Dréno of Nantes University Hôtel Dieu Hospital in France. Professor Dréno is Principal Investigator on a Phase I/II clinical trial involving patients with advanced (Stage IIIC or Stage IV) metastatic melanoma. Melanoma, although representing only about 5% of all skin cancer diagnoses, is the most deadly form of skin cancer and accounts for 40,000 deaths per year (which is more than 75% of all skin cancer deaths).

This trial is an investigator-led study in patients with Stage IIIC or Stage IV metastatic disease. The trial's therapeutic approach is to combine treatment with tumor infiltrating lymphocytes (TIL therapy) directed against melanoma proteins with the direct administration of TG1042 into melanoma lesions. The administration of TG1042 with TIL therapy is aimed at increasing the immune response to the cancerous melanoma cells. TIL therapy is an emerging approach to treating advanced melanoma and was the subject of several presentations at ASCO. Early TIL trial results reported at ASCO indicate that TIL therapy may be a promising new approach to treating patients with advanced melanoma. The trial is sponsored and funded in part by the Nantes University Hospital. Materials for the trial, consisting of TG1042 have been provided by Transgene.

"Virax is very pleased to add its support to the work of Professor Dréno and her colleagues in Nantes", said Dr. Larry Ward, Virax CEO. "It is very clear from the excitement surrounding all the new work in melanoma research that was announced at ASCO that the improved understanding of the role of immunotherapy for melanoma and other cancers will lead the way to better, more effective treatments."

Virax may, depending upon the outcome of the current trial, elect to provide additional support to future trials of TG1042 in the treatment of metastatic melanoma. Preliminary trial data is expected in early 2012. More detail on the trial can be found at the website: clinicaltrials.gov/show/NCT01082887.

About Professor Brigitte Dréno

Professor Dréno is a world leader in dermatological oncology with appointments at leading research hospitals and research institutes in France. Her appointments include: Head of Department of Dermatology and Skin Cancer in the University Hospital Nantes, Head of the GMP Centre of Cell and Gene and Cell Therapy and Director of the Centre of Clinical Investigation in Biotherapy (Inserm 0503). She is also coordinator of the Cancer Federation in Nantes Hospital.

Virax Holdings Limited

ABN 56 006 569 106
Suite 220, 89 High Street, Kew, Victoria 3101, Australia
Telephone: +61 (0) 3 9854 6230
Facsimile: +61 (0) 3 9853 5134

Email: virax@virax.com.au
www.virax.com.au

About Melanoma

Melanoma, although representing only about 5% of all skin cancer diagnoses, is the most deadly form of skin cancer and accounts for 40,000 deaths per year, which is more than 75% of all skin cancer deaths. According to projections by market research firm Datamonitor, the number of melanoma cases worldwide is expected to reach 227,000 by 2019. Melanoma is classified as superficial or invasive, with the invasive form being the more serious and life threatening. Invasive melanoma accounted for over half of all melanoma diagnoses in 2010. Melanoma affects both men and women. It is the 5th most common cancer in men and 6th most common cancer in women. It is expensive to treat. A study published in 2004 by the American Academy of Dermatology placed the direct cost of treating melanoma at \$1.5 billion.

For further information please contact:

Dr Larry Ward	John Morrison	James Moses
CEO	Company Secretary	Media and Investor Relations
Virax Holdings Ltd	Virax Holdings Ltd	Mandate Corporate
Ph: +61 (3) 9854 6230	Ph: +61 (3) 9854 6230	Ph: +61 420 991 574
E: lward@virax.com.au	E: jmorrisson@virax.com.au	E: james@mandatecoporate.com.au

About TG1042 skin cancer immunotherapeutic product

In February Virax announced that it had signed a worldwide exclusive License Agreement with leading French biopharmaceutical company Transgene (Eurolist Paris: FR0005175080) for Virax to develop TG1042 a clinical-stage skin cancer immunotherapy product (see ASX announcement of 14 February).

TG1042 is an adenoviral vector expressing interferon-gamma. It has been tested previously in humans in skin cancer indications for the treatment of cutaneous lymphomas (via intratumoral injection), where it has shown highly promising results in Phase I and Phase II Clinical Trials.

In Phase I Trials, patients with advanced cutaneous T-cell lymphoma (CTCL) and multi-lesional cutaneous B-cell lymphoma (CBCL), treatment with TG1042 induced a high overall response rate of local clinical responses.

In Phase II Clinical Trial of Intra-lesional administration of TG1042 (Adenovirus-interferon-gamma), patients with relapsing primary cutaneous B-cell lymphomas, the primary endpoint was met in the first step of the Phase II trial as measured by overall response rate.

This treatment was highly promising and on this basis was awarded Orphan Drug status by the European medical regulatory body, European Medicines Agency (EMA). In addition, the prior human testing of the product has significantly lowered the technical risk of the project in nodular BCC.

Skin cancers such as BCC and melanoma are huge problems in Australia. Australia is the premier location to conduct trials in BCC and melanoma, and the ability of Virax to run the trials in Australia is one of the strategic reasons underpinning the Transgene licence to Virax.

Skin Cancer Facts and Figures from Cancer Council Australia:

1. Skin cancers account for up to 80% of newly diagnosed cancers
2. Two in three Australians will be diagnosed with skin cancer by age 70
3. Skin cancer accounts for over 1 million GP consultations each year in Australia
4. Nearly 450,000 people are treated for one or more non-melanoma skin cancers each year
5. Australia has one of the highest incidences of skin cancer in the world, nearly 4 times the incidence in the US and Western Europe
6. Skin cancer is the most expensive cancer in Australia

Additional information is available at www.cancer.org.au

About Virax Holdings

Virax is an Australian biopharmaceutical company engaged in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. Its lead program is TG1042 skin cancer immunotherapy skin cancer treatment product. It acquired the TG1042 program from major French biotechnology company Transgene (Eurolist Paris: FR0005175080). Virax has a worldwide exclusive License Agreement with Transgene for Virax to develop TG1042.

The Company also recently completed a Phase IIa Clinical Trial on its VIR201 immunotherapeutic vaccine product for the treatment of HIV/AIDS, utilising Co-XGene™ technology.

Virax also has a Licence Agreement with Transgene, for Transgene to access Virax's Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products. These are; TG4001 – a treatment for pathologies relating to human papilloma virus (HPV) infection that can lead to cervical cancer, and TG4010 – a treatment for non-small cell lung cancer (NSCLC).